Inhibition of ERK signaling for treatment of ERRα positive TNBC
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0283047 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von David Musheyev und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Stony Brook Southampton Hospital, Southampton, New York, United States of America. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH, Applebaum Foundation.
Abstract (Originalsprache)
Breast cancer is the second leading cause of cancer-related deaths in women and triple-negative breast cancer (TNBC), in particular, is an aggressive and highly metastatic type of breast cancer that does not respond to established targeted therapies and is associated with poor prognosis and worse survival. Previous studies identified a subgroup of triple-negative breast cancer patients with high expression of estrogen related receptor alpha (ERRα) that has better prognosis when treated with tamoxifen. We therefore set out to identify common targets of tamoxifen and ERRα in the context of TNBC using phosphoproteomic analysis. In this study, we discovered that phosphorylation of mitogen-activated protein kinase 1 (MAPK1) is regulated by tamoxifen as well as ERRα. Additionally, we showed that inhibition of MAPK signaling together with the use of a selective ERRα inverse agonist, XCT-790, leads to a significant upregulation of apoptosis and paves way for the therapeutic use of MAPK inhibitors for treatment of ERRα expressing TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Stony Brook Southampton Hospital, Southampton, New York, United States of America.
- Department of Biology, Stern College for Women, Yeshiva University, New York, New York, United States of America.
- Department of Mechanical Engineering, Rutgers University, New Brunswick, New Jersey, United States of America.
ORCID-Profile: Natania Birnbaum, Anya Alayev
Förderung
- NCI NIH HHS
- NIH
- Applebaum Foundation
Zitieren
APA
Musheyev, D., Miller, E., Birnbaum, N., Miller, E., Erblich, S., Schuck, A., & Alayev, A. (2023). Inhibition of ERK signaling for treatment of ERRα positive TNBC. PLOS ONE. https://doi.org/10.1371/journal.pone.0283047
Vancouver
Musheyev D, Miller E, Birnbaum N, Miller E, Erblich S, Schuck A, et al. Inhibition of ERK signaling for treatment of ERRα positive TNBC. PLOS ONE. 2023. doi:10.1371/journal.pone.0283047
BibTeX
@article{Musheyev2023,
author = {Musheyev, David and Miller, Esther and Birnbaum, Natania and Miller, Elisheva and Erblich, Shoshana and Schuck, Alyssa and Alayev, Anya},
title = {Inhibition of ERK signaling for treatment of ERRα positive TNBC},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0283047}
}
EUVIMED